Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial.
AffiliationGynaecology Oncology Research Group, School of Cancer and Enabling Sciences, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractBody mass index (BMI) is a major risk factor for endometrial cancer incidence but its impact on post-treatment survival is unclear. We investigated the relationships of BMI (categorised using the WHO definitions) with clinico-pathological characteristics and outcome in women treated within the MRC ASTEC randomised trial, which provides data from patients who received standardised allocated treatments and therefore reduces biases. The impact of BMI on both recurrence-free survival (RFS) and overall survival (OS) was analysed using the Cox regression models. An apriori framework of evaluating potential biases was explored. From 1408 participants, there were 1070 women with determinable BMI (median=29.1 kg/m(2)). Histological types were endometrioid (type 1) in 893 and non-endometrioid (type 2) in 146 women; the proportion of the latter decreasing with increasing BMI (8% versus 19% for obese III WHO category versus normal weight, p(trend)=0.003). For type 1 carcinomas, increasing BMI was associated with less aggressive histopathological features (depth of invasion, p=0.006; tumour grade, p=0.015). With a median follow-up of 34.3 months, there was no influence of BMI on RFS - adjusted HRs per 5 kg/m(2) were 0.98 (95% CI 0.86, 1.13) and 0.95 (0.74, 1.24), for type 1 and 2 carcinomas; and no influence on OS - adjusted HRs per 5 kg/m(2) were 0.96 (0.81, 1.14) and 0.92 (0.70, 1.23), respectively. These findings demonstrate an important principle: that an established link between an exposure (here, obesity) and increased incident cancer risk, does not necessarily translate into an inferior outcome following treatment for that cancer.
CitationBody mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. 2012, 48 (6):853-64 Eur J Cancer
JournalEuropean Journal of Cancer
- Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer.
- Authors: Robbins JR, Gayar OH, Zaki M, Mahan M, Buekers T, Elshaikh MA
- Issue date: 2013 Dec
- High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.
- Authors: Mauland KK, Trovik J, Wik E, Raeder MB, Njølstad TS, Stefansson IM, Oyan AM, Kalland KH, Bjørge T, Akslen LA, Salvesen HB
- Issue date: 2011 Mar 15
- Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer.
- Authors: Reynaers EA, Ezendam NP, Pijnenborg JM
- Issue date: 2015 May
- Severe Obesity Impacts Recurrence-Free Survival of Women with High-Risk Endometrial Cancer: Results of a French Multicenter Study.
- Authors: Canlorbe G, Bendifallah S, Raimond E, Graesslin O, Hudry D, Coutant C, Touboul C, Bleu G, Collinet P, Darai E, Ballester M
- Issue date: 2015 Aug
- An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
- Authors: Gadducci A, Cosio S, Fanucchi A, Cristofani R, Genazzani AR
- Issue date: 2000 May-Jun